Only two weeks after disappointing news on its Alzheimer's disease candidate, Dimebon (latrepirdine), Medivation Inc. had better news to share. Data from its Phase III AFFIRM trial of prostate cancer drug MDV3100, which will be presented later this week, were highlighted in a press conference put on by the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium Tuesday.